Cabaletta Bio Inc (CABA)
10.66
-1.90
(-15.13%)
USD |
NASDAQ |
Jun 14, 16:00
10.65
-0.01
(-0.09%)
After-Hours: 20:00
Cabaletta Bio Research and Development Expense (TTM): 64.94M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 64.94M |
| December 31, 2023 | 55.42M |
| September 30, 2023 | 50.42M |
| June 30, 2023 | 44.85M |
| March 31, 2023 | 42.56M |
| December 31, 2022 | 39.30M |
| September 30, 2022 | 36.82M |
| June 30, 2022 | 36.77M |
| March 31, 2022 | 35.11M |
| December 31, 2021 | 32.49M |
| Date | Value |
|---|---|
| September 30, 2021 | 28.35M |
| June 30, 2021 | 25.83M |
| March 31, 2021 | 23.31M |
| December 31, 2020 | 21.38M |
| September 30, 2020 | 18.63M |
| June 30, 2020 | 16.20M |
| March 31, 2020 | 13.53M |
| December 31, 2019 | 11.67M |
| September 30, 2019 | 9.884M |
| June 30, 2019 | 9.253M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
9.253M
Minimum
Jun 2019
64.94M
Maximum
Mar 2024
30.84M
Average
30.42M
Median
Research and Development Expense (TTM) Benchmarks
| Editas Medicine Inc | 188.63M |
| ACADIA Pharmaceuticals Inc | 342.15M |
| Alnylam Pharmaceuticals Inc | 1.035B |
| Regeneron Pharmaceuticals Inc | 4.586B |
| Vertex Pharmaceuticals Inc | 3.209B |